Brief: Egetis Therapeutics FY Adjusted EPS SEK -1.3
22/02/2024 06:00
Feb 22 (Reuters) - Egetis Therapeutics FY revenue SEK 57.6 million vs. IBES estimate SEK 36.2 million. * FY net income SEK -326.9 million
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1